Abstract |
The tumor inhibiting effect of a newly developed bifunctional nitrosoureido derivative (GYKI-13324) was studied on human colorectal tumor xenograft lines. Given orally in single or multiple daily doses, GYKI-13324 produced long-term or total regression of adenomatous, but only marginal growth delay of mucinous tumors. GYKI-13324, with slightly lower toxicity than that of BCNU, seems to be a candidate in the clinical management of colorectal tumors.
|
Authors | L Kopper, K Lapis, E Csányi, T Horváth |
Journal | Anticancer research
(Anticancer Res)
Vol. 1
Issue 4
Pg. 229-33
( 1981)
ISSN: 0250-7005 [Print] Greece |
PMID | 7345967
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- GYKI 13324
- Carmustine
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Carmustine
(pharmacology)
- Cell Division
(drug effects)
- Cell Line
- Colonic Neoplasms
(drug therapy)
- Humans
- Mice
- Mice, Inbred CBA
- Neoplasm Transplantation
- Nitrosourea Compounds
(pharmacology)
- Rectal Neoplasms
(drug therapy)
- Transplantation, Heterologous
|